// App-Quantinova.ai

: Concerns about Prognostic Meaning of Quantitative PET Analysis in Classical Hodgkin Lymphoma

Researchers

Presenter

  • Fernanda Maria Maria Santos

Principal Investigators

  • José Flávio Gomes Marin

  • Marcos Santos Lima

  • Wellington F Silva

  • Rodrigo D Velasques

  • Ana Carolina Arrais Maia

  • Marcelo Junqueira Atanazio

  • Lucas Bassolli de Oliveira Alves

  • Frederico Rafael Moreira

  • Carlos Alberto Buchpiguel

  • Valeria Buccheri

  • Vanderson Rocha

Medical Centers

  • Instituto do Cancer de São Paulo (ICESP), University of Sao Paulo (USP), Sao Paulo, Brazil

  • Department of Hematology, Churchill Hospital, NHS BT, Oxford University, Oxford, United Kingdom

  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil

  • Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil

  • Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology, Department of Hematology (LIM-), University of Sao Paulo, São Paulo, Brazil

  • Department of Hematology, Hemotherapy and Cell Therapy, University of São Paulo, São Paulo, Brazil

  • Nuclear Medicine Medical Investigation Laboratory LIM, Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil

  • Hospital das Clínicas da Universidade de São Paulo, University of Sao Paulo (USP), São Paulo, Brazil

  • Service of Hematology, Transfusion and Cell Therapy, and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-), Hospital das Clinicas, Faculty of Medicine, Sao Paulo University (FM-USP), Sao Paulo, Brazil

  • Medical Research Laboratory on Molecular Hematology (LIM-), Universidade de São Paulo, São Paulo, Brazil

Locations

  • Brazil

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • Total lesion glycolysis

Drug/Treatment

  • N/A

Outcome

  • N/A


Study Design

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A